 | In a letter to the Institute for Clinical and Economic Review (ICER), PIPC submitted feedback on ICER's assessment of treatments nonalcoholic steatohepatitis (NASH). |
The letter notes that ICER's assessment seems to mischaracterize certain aspects of NASH, which leads to an underestimation of the importance of treatment and a flawed model. ICER's model also ignores the wide public health value of reduced demand for liver transplants.
"Diagnosis and treatment of NASH is imperative to stem these more serious outcomes," wrote PIPC Chair Tony Coelho. "PIPC urges ICER to go review its report alongside experts in the field of liver disease, including patients and providers to ensure that it is accurately representing NASH and its modeling choices can lead to an accurate representation of value to this community."
"Diagnosis and treatment of NASH is imperative to stem these more serious outcomes," wrote PIPC Chair Tony Coelho. "PIPC urges ICER to go review its report alongside experts in the field of liver disease, including patients and providers to ensure that it is accurately representing NASH and its modeling choices can lead to an accurate representation of value to this community."
| icer_nash_23_final_for_submission.pdf |
